Beta Bionics, Inc. SEC Filings

Stephen Feider, Chief Financial Officer of Beta Bionics, Inc. (BBNX), reported transactions dated 09/05/2025. He exercised an employee stock option to acquire 100 shares at an exercise price of $5.10 and simultaneously sold 100 shares at $21.00 pursuant to a Rule 10b5-1 trading plan adopted on May 15, 2025. After these transactions he beneficially owned 44,041 shares of common stock directly.

The option exercised was part of an employee stock option award exercisable beginning in September 2023 and expiring 09/13/2033; the filing shows 99,595 derivative securities (options) beneficially owned following the reported transactions. The form is signed and dated 09/08/2025.

Form 144 notice for Beta Bionics, Inc. (BBNX): The filing reports a proposed sale of 9,900 common shares through Merrill Lynch on 09/08/2025 on NASDAQ with an aggregate market value of $209,152.15. The shares were acquired the same day as stock options from the issuer and paid in cash. The filing lists total shares outstanding as 43,470,125. Recent insider sales by Stephen Feider are included: 1,497 shares on 06/02/2025 for $26,783.06; 5,587 on 08/19/2025 for $95,171.78; 4,413 on 08/22/2025 for $75,082.65; and 100 on 09/05/2025 for $2,100.00. Several standard filer and issuer identifier fields are blank in the provided content.

Beta Bionics, Inc. (BBNX) Form 144 notifies a proposed sale of 11,411 common shares through Merrill Lynch with an aggregate market value of $234,656.73, scheduled approximately for 09/05/2025 on NASDAQ. The filing shows the shares were acquired the same day as a stock option exercise and paid in cash. The filer (person for whose account the shares will be sold) recorded prior open-market dispositions in the past three months totaling 23,844 shares for gross proceeds of $420,084.80 on 06/02/2025, 08/19/2025 and 09/04/2025. The notice includes the required signature representation about absence of undisclosed material information.

Form 144 notice for Beta Bionics, Inc. (BBNX) shows a proposed sale of 100 common shares through Merrill Lynch on NASDAQ with an aggregate market value of $2,100. The filing identifies the shares as acquired on 09/05/2025 by exercise of stock options from the issuer and paid in cash the same date. The filer has executed several recent open-market sales: 4,413 shares on 08/22/2025 for $75,082.65, 5,587 shares on 08/19/2025 for $95,171.78, and 1,497 shares on 06/02/2025 for $26,783.06. The notice includes the standard representation that the seller attests not to possess undisclosed material adverse information.

Beta Bionics, Inc. (BBNX) reporting person "Saint Sean" (identified as President & CEO and Director) executed a non-derivative sale of 3,359 common shares on 09/02/2025 at a weighted average sale price of $18.8632 per share, with the reported price range between $18.58 and $19.09. The filing states the shares were sold to cover tax withholding obligations tied to the vesting of restricted stock units. After the transaction, the reporting person is shown as beneficially owning 101,202 shares. The Form 4 was signed by an attorney-in-fact on 09/03/2025.

Russell Steven Jon, identified as the Chief Medical Officer of Beta Bionics, Inc. (BBNX), reported a sale of 1,015 shares of the issuer's common stock on 09/02/2025. The filing states the sale was executed to cover tax withholding obligations tied to the vesting of restricted stock units. The weighted average sale price was $18.8632, with individual trade prices ranging from $18.58 to $19.09. After the transaction the reporting person beneficially owned 71,017 shares. The Form 4 was signed by an attorney-in-fact on 09/03/2025.

Beta Bionics insider sale to cover taxes on RSU vesting. Chief Product Officer Mike Mensinger sold 1,089 shares of Beta Bionics common stock on 09/02/2025 at a weighted average price of $18.8632, with the transaction price range between $18.58 and $19.09. After the sale, Mensinger beneficially owned 91,815 shares, reported as direct ownership. The filing states the sale was made to satisfy tax withholding obligations tied to restricted stock unit vesting; no option exercises or derivative transactions were reported. The form was signed by an attorney-in-fact on 09/03/2025.

Mark Hopman, identified as the Chief Commercial Officer of Beta Bionics, Inc. (BBNX), reported a transaction on 09/02/2025. The filing shows 848 shares of Common Stock were sold to cover tax withholding obligations related to restricted stock unit vesting. The weighted average sale price was $18.8632, with individual sale prices ranging from $18.58 to $19.09. After the reported transaction, Hopman beneficially owned 33,284 shares directly. The Form 4 was signed by an attorney-in-fact on 09/03/2025.

Stephen Feider, identified as an officer (Chief Financial Officer) of Beta Bionics, Inc. (BBNX), reported a sale of common stock on 09/02/2025. The Form 4 shows 1,462 shares were sold to cover tax withholding obligations tied to the vesting of restricted stock units. The weighted average sale price was $18.8632, with prices ranging from $18.58 to $19.09. After the transaction, Mr. Feider beneficially owned 44,041 shares (reported as direct ownership). The filing is signed by Stephen Feider on 09/03/2025. No derivative transactions or other changes are reported.